在线注册截止时间为 2024 年 6 月 4 日(美国东部时间 12:00)。 ●3.注册费用:因是否为 ASCO 会员、现场/线上参会形式而异(详情请看:https://conferences.asco.org/am/registration)。 ●4. 在线参会:若因其他日程安排缘由等无法前往现场与会,您...
在线注册截止时间为 2024 年 6 月 4 日(美国东部时间 12:00)。 ●3.注册费用:因是否为 ASCO 会员、现场/线上参会形式而异(详情请看:https://conferences.asco.org/am/registration)。 ●4. 在线参会:若因其他日程安排缘由等无法前往现场与会,您还可以选择线上参会,全程直播、会后回放均可看 (线上直播链...
a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study[J]. Annals of Oncology, 2023, 34(Supplement 4): S16...
jul 13, 2025 online & in-person | minneapolis, mn register registration deadline: july 12, 2025 save the date quality care symposium oct 10 - oct 12, 2025 online & in-person | chicago, il subscribe for updates arrow_back_ios arrow_forward_ios most viewed text_snippet videos & slides ...
Clinical Trial Registration Number:NCT05315167 发布日期:2024.05 摘要号:2590 YF550-C1小分子抑制剂研究摘要海报细节展示如下: 题目: YF550-C1, an E3 ligase inhibitor of Cbl-b, to demonstrate T cell and NK cell ac-tivation and anti-tumor activities in syngeneic and PDX tumor model ...
Registration for Healthcare professionals can be completed above. Industry representatives (both sponsor and non-sponsor) must contact Kelly Allan at kelly@oncologyeducation.ca for registration and sponsorship opportunities. Industry registrations will not be accepted through the website.Sponsorship For...
(DCR), PFS rate at 6 months and 12 months, OS rate at 6 months and 12 months, DCR, quality of life score(QoL), and nutritional score PG-SGA. As of February 2024, eight patients have been enrolled in the study. Trial registration number: ChiCTR2300077213. Clinical trial information:...
Building on the strong understanding of the role of KEYTRUDA in later-stage cancers, Merck is studying KEYTRUDA in earlier disease states, with more than 25 ongoing registrational studies across multiple types of cancer. About KEYTRUDA...
TILVANCE-301 is a global, randomized, registrational Phase 3 trial to support accelerated and full U.S. approvals of lifileucel in combination with pembrolizumab in frontline advanced melanoma. In addition, the ORR endpoint in TILVANCE-301 supports full approval of lifileucel monothera...
2023年美国临床肿瘤学会胃肠癌研讨会ASCO GI 2023 将于 2023 年 1 月 19 日至 21 日在加利福尼亚州旧金山举行。Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, ASCO GI 2023,ASCO 胃肠癌研讨会是一项备受瞩目的专业肿瘤学活动,旨在交流胃肠癌预防、诊断和多学科治疗方面的最新研...